AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9649142 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 90 mg/m² i.v. every 3 weeks
Number of subjects: 232
Study 8081406 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 18
Study 8081406 — intervention group
Group type: COMPARATOR
Intervention: Voluntary isometric contraction (traditional exercise)
Number of subjects: 18
Study 2642543 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of COMP therapy (cyclophosphamide, vincristine, methotrexate, and prednisone)
Number of subjects: 232
Study 2642543 — intervention group
Group type: COMPARATOR
Intervention: 18 months of COMP therapy (cyclophosphamide, vincristine, methotrexate, and prednisone)
Number of subjects: 232
Study 55529 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg orally three times a week on alternate weeks)
Number of subjects: 43
Study 55529 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 43
Study 31415063 — intervention group
Group type: COMPARATOR
Intervention: Control group (facility-based lymphedema care with no home-based exercise or weight loss intervention)
Number of subjects: 351
Study 31415063 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (strength/resistance training twice per week and 180 minutes of walking per week)
Number of subjects: 351
Study 31415063 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (20 weeks of meal replacements and 52 weeks of lifestyle modification counseling)
Number of subjects: 351
Study 31415063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and weight loss intervention
Number of subjects: 351
Study 28406774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the thoracic duct
Number of subjects: 60
Study 28406774 — intervention group
Group type: COMPARATOR
Intervention: No ligation of the thoracic duct
Number of subjects: 60
Study 25759413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish skin acellular dermal matrix (ADM)
Number of subjects: 81
Study 25759413 — intervention group
Group type: COMPARATOR
Intervention: Porcine small-intestine submucosa extracellular matrix
Number of subjects: 81
Study 23739758 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 34
Study 23739758 — intervention group
Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 34
Study 23739758 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound therapy (UST)
Number of subjects: 34
Study 21276962 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 36
Study 21276962 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (treatment-as-usual, TAU)
Number of subjects: 36
Study 18759522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (100 IU/kg subcutaneously twice a day for 10 days, then 100 IU/kg once a day for another 10 days)
Number of subjects: 47
Study 18759522 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg daily throughout the study)
Number of subjects: 47
Study 18759522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 47
Study 18759522 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 47
Study 15921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in left amygdala, lentiform nucleus, and parahippocampal gyrus
Number of subjects: 15
Study 15921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in right rostral and subgenual anterior cingulate cortices, insula and claustrum
Number of subjects: 15
Study 15921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in right antero‐lateral orbitofrontal cortex
Number of subjects: 15
Study 15921853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in right postero‐medial orbitofrontal cortex and left lentiform nucleus
Number of subjects: 15
Study 12374537 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of a standard sun protection factor 15+ broad-spectrum retail sunscreen to the head and neck, arms, and hands.
Number of subjects: 0
Study 10424402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES)
Number of subjects: 151
Study 10424402 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 151
Study 7493297 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b (group A)
Number of subjects: 40
Study 7493297 — intervention group
Group type: COMPARATOR
Intervention: IFN-beta (group B)
Number of subjects: 40
Study 7493297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFN types
Number of subjects: 40
Study 7493297 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (group A)
Number of subjects: 40
Study 7493297 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta
Number of subjects: 40
Study 2268495 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided design (written simulations and small group interaction)
Number of subjects: 50
Study 2268495 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 50
Study 499311 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI) 75 mg daily for 3 days
Number of subjects: 0
Study 499311 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 750 mg
Number of subjects: 0
Study 499311 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI)
Number of subjects: 0
Study 499311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant drugs
Number of subjects: 0
Study 31022754 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sodium concentration ≤136 mmol/L
Number of subjects: 80
Study 31022754 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sodium concentration on admission
Number of subjects: 80
Study 31022754 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma AVP on admission
Number of subjects: 80
Study 31022754 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sodium concentration as a diagnostic marker
Number of subjects: 80
Study 29460813 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg vitamin B12 daily for 8 weeks
Number of subjects: 95
Study 29460813 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement for 8 weeks
Number of subjects: 95
Study 26790758 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS administration (0.4–0.8 ng/kg body weight)
Number of subjects: 186
Study 25330848 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week exercise and diet guidance intervention
Number of subjects: 38
Study 23081705 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0
Study 23081705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20642382 — intervention group
Group type: EXPERIMENTAL
Intervention: drospirenone + ethinylestradiol + oral L-arginine (4 g × 2/daily)
Number of subjects: 28
Study 20642382 — intervention group
Group type: COMPARATOR
Intervention: drospirenone + ethinylestradiol + placebo
Number of subjects: 28
Study 18045691 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity individualized treadmill training (HI)
Number of subjects: 30
Study 18045691 — intervention group
Group type: COMPARATOR
Intervention: Lower intensity generalized training (LG)
Number of subjects: 30
Study 16163916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral neck X-ray
Number of subjects: 100
Study 16163916 — intervention group
Group type: COMPARATOR
Intervention: Mallampati Class test
Number of subjects: 100
Study 14579087 — intervention group
Group type: COMPARATOR
Intervention: Gradient histogram in the parieto-temporal lobes
Number of subjects: 87
Study 14579087 — intervention group
Group type: COMPARATOR
Intervention: Count density/voxel histogram (frontal and occipital lobes) and mean gradient (frontal, temporal and parietal lobes)
Number of subjects: 87
Study 14579087 — intervention group
Group type: EXPERIMENTAL
Intervention: Count density/voxel histogram in the frontal, parietal and occipital lobes
Number of subjects: 87
Study 14579087 — intervention group
Group type: EXPERIMENTAL
Intervention: Concatenated joint feature
Number of subjects: 87
Study 14579087 — intervention group
Group type: EXPERIMENTAL
Intervention: 5D co-occurrence matrices
Number of subjects: 87
Study 11038091 — intervention group
Group type: EXPERIMENTAL
Intervention: French osteotomy
Number of subjects: 25
Study 11038091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dome osteotomy
Number of subjects: 25
Study 9093710 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine + interferon-alpha (IFN-alpha-2a)
Number of subjects: 30
Study 9093710 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine alone
Number of subjects: 30
Study 8444226 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg of 20% albumin infusion
Number of subjects: 30
Study 8444226 — intervention group
Group type: COMPARATOR
Intervention: 5 ml/kg of maintenance fluids (placebo)
Number of subjects: 30
Study 8444226 — intervention group
Group type: COMPARATOR
Intervention: Both groups (albumin and placebo)
Number of subjects: 30
Study 3942669 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of water with diazepam tablets (group A)
Number of subjects: 33
Study 3942669 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml of water with diazepam tablets (group B)
Number of subjects: 33
Study 29610265 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception blood pressure (systolic: 111.6 mm Hg, diastolic: 72.5 mm Hg)
Number of subjects: 1228
Study 29610265 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception blood pressure
Number of subjects: 1228
Study 27354129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (1000 mg orally twice daily during and for 4 weeks after RT)
Number of subjects: 87
Study 27354129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally twice daily during and for 4 weeks after RT)
Number of subjects: 87
Study 27354129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 87
Study 27354129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 24397244 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon catheter with EASI
Number of subjects: 186
Study 24397244 — intervention group
Group type: COMPARATOR
Intervention: Single balloon catheter with EASI
Number of subjects: 186
Study 22540161 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 IU kg(‐1) rhFVIII
Number of subjects: 12
Study 22540161 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 IU kg(‐1) rhFVIII
Number of subjects: 12
Study 22540161 — intervention group
Group type: COMPARATOR
Intervention: TB-402
Number of subjects: 12
Study 20080466 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-targeting drugs (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib)
Number of subjects: 0
Study 20080466 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3K‐mTOR inhibitors (temsirolimus, everolimus)
Number of subjects: 0
Study 18396444 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 57
Study 18396444 — intervention group
Group type: EXPERIMENTAL
Intervention: Parapharyngeal invasion
Number of subjects: 57
Study 18396444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernous sinus invasion
Number of subjects: 57
Study 18396444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor vascular invasion
Number of subjects: 57
Study 18396444 — intervention group
Group type: EXPERIMENTAL
Intervention: Parapharyngeal and cavernous sinus invasion
Number of subjects: 57
Study 15812585 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonyautoxin infiltration (100 units in 1 ml)
Number of subjects: 50
Study 12413670 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes (papain, trypsin, chymotrypsin)
Number of subjects: 56
Study 12413670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 10797108 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.5% glucose polymer
Number of subjects: 7
Study 10797108 — intervention group
Group type: EXPERIMENTAL
Intervention: 18.5% sucrose
Number of subjects: 7
Study 10797108 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sucrose
Number of subjects: 7
Study 8882257 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of 2 ml of patient's blood into propofol
Number of subjects: 100
Study 8882257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 20 mg added to propofol
Number of subjects: 100
Study 8882257 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 ml added to propofol
Number of subjects: 100
Study 1467072 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 30
Study 1467072 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 30
Study 1467072 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 3918653 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.64 mg glyceryl trinitrate
Number of subjects: 10
Study 3918653 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg isosorbide dinitrate
Number of subjects: 10
Study 3918653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31096027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 789
Study 31096027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for breast cancer-specific survival (BCSS) prediction
Number of subjects: 789
Study 31096027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predictions for OS and BCSS
Number of subjects: 789
Study 29808262 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ml of 0.25% levobupivacaine + 1 ml (20 mg) nalbuphine
Number of subjects: 135
Study 29808262 — intervention group
Group type: COMPARATOR
Intervention: 25 ml of 0.5% levobupivacaine + 1 ml normal saline
Number of subjects: 135
Study 29808262 — intervention group
Group type: COMPARATOR
Intervention: 25 ml of 0.25% levobupivacaine + 1 ml normal saline
Number of subjects: 135
Study 26939572 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK672 90 mg twice daily
Number of subjects: 90
Study 26939572 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK672 10-90 mg twice daily
Number of subjects: 90
Study 26939572 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK672
Number of subjects: 90
Study 26939572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26939572 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 90
Study 23819250 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment and routine western medicine
Number of subjects: 60
Study 23819250 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 60
Study 21838089 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized tretinoin gel 0.05%
Number of subjects: 483
Study 21838089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.1%
Number of subjects: 483
Study 21838089 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 483
Study 19480872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (10 minutes)
Number of subjects: 53
Study 19480872 — intervention group
Group type: COMPARATOR
Intervention: Barrel-sitting (10 minutes)
Number of subjects: 53
Study 19480872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (12 weekly sessions)
Number of subjects: 53
Study 16500773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 33
Study 16500773 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Number of subjects: 33
Study 14711911 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b
Number of subjects: 330
Study 14711911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 11717598 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 100
Study 11717598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9205393 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic bed
Number of subjects: 256
Study 8181020 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic modalities for managing ventricular arrhythmias in CHF
Number of subjects: 0
Study 3584746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate
Number of subjects: 17
Study 3584746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31496270 — intervention group
Group type: EXPERIMENTAL
Intervention: Early numeracy Tier 2 intervention delivered four days per week for 20 weeks.
Number of subjects: 121
Study 31496270 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (control group).
Number of subjects: 121
Study 30467977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal samples
Number of subjects: 31
Study 30467977 — intervention group
Group type: COMPARATOR
Intervention: Colonic biopsies
Number of subjects: 31
Study 27016618 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg IV-TXA
Number of subjects: 124
Study 27016618 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg IV-TXA
Number of subjects: 124
Study 27016618 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 124
Study 24193993 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 or 200 mg of lidocaine injections
Number of subjects: 62
Study 24193993 — intervention group
Group type: COMPARATOR
Intervention: saline injections
Number of subjects: 62
Study 23535609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal lipid-based nutrient supplements (LNSs)
Number of subjects: 197
Study 23535609 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient tablets
Number of subjects: 197
Study 20955281 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated comorbidity assessments
Number of subjects: 1846
Study 20955281 — intervention group
Group type: COMPARATOR
Intervention: Baseline comorbidity assessments
Number of subjects: 1846
Study 18219348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin subcutaneously every day for 20 days
Number of subjects: 0
Study 18219348 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) daily for 20 days
Number of subjects: 0
Study 21033082 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine treatment for NAFLD
Number of subjects: 0
Study 16282543 — intervention group
Group type: EXPERIMENTAL
Intervention: PCK1‐232G/G genotype
Number of subjects: 150
Study 16282543 — intervention group
Group type: COMPARATOR
Intervention: Other genotypes
Number of subjects: 150
Study 12048150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype suppression instructions in experiment 1
Number of subjects: 110
Study 12048150 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype suppression instructions in experiment 2
Number of subjects: 110
Study 12048150 — intervention group
Group type: COMPARATOR
Intervention: Previous contact with persons with mental illness
Number of subjects: 110
Study 9721990 — intervention group
Group type: EXPERIMENTAL
Intervention: Videomanometry
Number of subjects: 0
Study 9721990 — intervention group
Group type: COMPARATOR
Intervention: Healthy age‐matched controls
Number of subjects: 0
Study 7990065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis sessions (3 sessions)
Number of subjects: 5
Study 7990065 — intervention group
Group type: COMPARATOR
Intervention: Non-hypnotic sessions (3 sessions)
Number of subjects: 5
Study 3178924 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 3178924 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 0
Study 3178924 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (both doses)
Number of subjects: 0
Study 12380852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed personalized normative feedback (PNF)
Number of subjects: 100
Study 12380852 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (C)
Number of subjects: 100
Study 30081012 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 126
Study 30081012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 26980216 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous para‐aneurysmal saline injection
Number of subjects: 51
Study 24140072 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 134
Study 24140072 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 134
Study 22337474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead Sea salt (DSS) irrigations and DSS nasal spray
Number of subjects: 114
Study 22337474 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone spray and hypertonic saline irrigation and spray
Number of subjects: 114
Study 20176716 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography for AV interval optimization
Number of subjects: 20
Study 20176716 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography for VV interval optimization
Number of subjects: 20
Study 20176716 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic methods for AV/VV interval optimization
Number of subjects: 20
Study 18419328 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (11 mL)
Number of subjects: 140
Study 18419328 — intervention group
Group type: COMPARATOR
Intervention: 40% DMSO with lidocaine (10 mL)
Number of subjects: 140
Study 15756405 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 20
Study 15756405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 20
Study 12463727 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (XV459) 0.5 to 1.25 mg daily for 7 to 10 days
Number of subjects: 41
Study 10348512 — intervention group
Group type: EXPERIMENTAL
Intervention: mylohyoid nerve block + IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine + 3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 30
Study 10348512 — intervention group
Group type: EXPERIMENTAL
Intervention: mock mylohyoid nerve block + IAN block (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 30